ELSEVIER

Journal of Affective Disorders 79 (2004) 307–309

JOURNAL OF AFFECTIVE DISORDERS

www.elsevier.com/locate/jad

# Author index

Allen, M.T., see Straneva-Meuse, P.A. (79) 51
Amos, T., see Douglas, J. (79) 263
Appleby, L., see Douglas, J. (79) 263
Aro, H., see Hämäläinen, J. (79) 105

Baethge, C., Gruschka, P., Berghöfer, A., Bauer, M., Müller-Oerlinghausen, B., Bschor, T. and Smolka, M.N.
Prophylaxis of schizoaffective disorder with lithium or carbamazepine: outcome after long-term follow-up (79) 43
Ballesteros, J. and Callado, L.F.
Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials (79) 137
Barkow, K., Heun, R., Wittchen, H.-U., Bedirhan Üstün, T., Gänsicke, M. and Maier, W.
Mixed anxiety–depression in a 1 year follow-up study: shift to other diagnoses or remission? (79) 235
Barnett, B., see Matthey, S. (79) 113
Barrot, I., see Millet, B. (79) 241
Bauer, M., see Baethge, C. (79) 43
Bech, P., see Martiny, K. (79) 253
Bedirhan Üstün, T., see Barkow, K. (79) 235
Benedetti, A., Lattanzi, L., Pini, S., Musetti, L., Dell'Osso, L. and Cassano, G.B.
Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode (79) 273
Berghöfer, A., see Baethge, C. (79) 43
Blairy, S., Linotte, S., Souery, D., Papadimitriou, G.N., Dikeos, D., Lerer, B., Kaneva, R., Milanova, V., Serretti, A., Macciardi, F. and Mendlewicz, J.
Social adjustment and self-esteem of bipolar patients: a multicentric study (79) 97
Bourdel, M.C., see Millet, B. (79) 241
Boyce, P., see Wilhelm, K. (79) 33
Bravo, M., see Ezquiaga, E. (79) 63
Brownhill, S., see Wilhelm, K. (79) 33
Bschor, T., see Baethge, C. (79) 43
Bullock, T., see Sampson, E. (79) 223

Callado, L.F., see Ballesteros, J. (79) 137
Carpenter, L.L., Heninger, G.R., Malison, R.T., Tyrka, A.R. and Price, L.H.
Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression (79) 285
Cassano, G.B., see Benedetti, A. (79) 273
Charles, M., see Matthey, S. (79) 113
Chawky, N., see Lalovic, A. (79) 25
Cissé, M., see Karege, F. (79) 187
Clemmensen, L., see Martiny, K. (79) 253
Cohen, L.S., see Harlow, B.L. (79) 167
Cooper, J., see Douglas, J. (79) 263
Cramer, D.W., see Harlow, B.L. (79) 167
Csábi, G., seeényi, T. (79) 259
Cuijpers, P., de Graaf, R. and van Dorsselaer, S.
Minor depression: risk profiles, functional disability, health care use and risk of developing major depression (79) 71

D'Argenio, A., see Troisi, A. (79) 269
De Dios, C., see Ezquiaga, E. (79) 63
De Graaf, R., see Cuijpers, P. (79) 71
DeGuzman, R., see Lalovic, A. (79) 25
Dell'Osso, L., see Benedetti, A. (79) 273
Demonfaucon, F., see Millet, B. (79) 241
Dikeos, D., see Blairy, S. (79) 97
Douglas, J., Cooper, J., Amos, T., Webb, R., Guthrie, E. and Appleby, L.
"Near-fatal" deliberate self-harm: characteristics, prevention and implications for the prevention of suicide (79) 263
Dyer, E.J., see Khawaja, N.G. (79) 217

Erickson, M., see Price, J.S. (79) 1
Ezquiaga, E., García-López, A., de Dios, C., Leiva, A., Bravo, M. and Montejo, J.
Clinical and psychosocial factors associated with the outcome of unipolar major depression: a one year prospective study (79) 63

Fava, M., see Perlis, R.H. (79) 291
Ferrando, L., see Montes, J.M. (79) 229
Franke, L., see Müller-Oerlinghausen, B. (79) 13

Gallarda, T., see Millet, B. (79) 241
Gänsicke, M., see Barkow, K. (79) 235
García-López, A., see Ezquiaga, E. (79) 63
Gardner Jr., R., see Price, J.S. (79) 1
Gilbert, J., see Gilbert, P. (79) 149
Gilbert, P., Gilbert, J. and Irons, C.
Life events, entrapments and arrested anger in depression (79) 149
Girdler, S.S., see Straneva-Meuse, P.A. (79) 51
Goering, P., see Gratzer, D. (79) 209
Golding, M., see Straneva-Meuse, P.A. (79) 51

doi:10.1016/S0165-0327(04)00066-7

Gratzer, D., Levitan, R.D., Sheldon, T., Toneatto, T., Rector, N.A. and Goering, P.
Lifetime rates of alcoholism in adults with anxiety, depression, or co-morbid depression/anxiety: a community survey of Ontario (79) 209
Greenfield, S.F., see Weiss, R.D. (79) 279
Griffin, M.L., see Weiss, R.D. (79) 279
Gruschka, P., see Baethge, C. (79) 43
Guthrie, E., see Douglas, J. (79) 263

Hämäläinen, J., Isometsä, E., Laukkala, T., Kaprio, J., Poikolainen, K., Heikkinen, M., Lindeman, S. and Aro, H.
Use of health services for major depressive episode in Finland (79) 105
Hantouche, E.G., see Millet, B. (79) 241
Harlow, B.L., Cohen, L.S., Otto, M.W., Spiegelman, D. and Cramer, D.W.
Early life menstrual characteristics and pregnancy experiences among women with and without major depression: the Harvard study of moods and cycles (79) 167
Hedges, D.W., see Preston, G.A. (79) 297
Heikkinen, M., see Hämäläinen, J. (79) 105
Heimberg, R.G., see Stein, M.B. (79) 161
Heninger, G.R., see Carpenter, L.L. (79) 285
Heun, R., see Barkow, K. (79) 235
Howie, P., see Matthey, S. (79) 113

Ialongo, N., McCreary, B.K., Pearson, J.L., Koenig, A.L., Schmidt, N.B., Poduska, J. and Kellam, S.G.
Major depressive disorder in a population of urban, African-American young adults: prevalence, correlates, comorbidity and unmet mental health service need (79) 127
Irons, C., see Gilbert, P. (79) 149
Isometsä, E., see Hämäläinen, J. (79) 105

Jacobson, L.M., see Weiss, R.D. (79) 279
Jeges, S., see Tényi, T. (79) 259

Kalaria, R.N., see Thomas, A.J. (79) 81
Kaneva, R., see Blairy, S. (79) 97
Kaprio, J., see Hämäläinen, J. (79) 105
Karege, F., Schwald, M., Papadimitriou, P., Lachausse, C. and Cissé, M.
The cAMP-dependent protein kinase A and brain-derived neurotrophic factor expression in lymphoblast cells of bipolar affective disorder (79) 187
Kavanagh, J.J., see Matthey, S. (79) 113
Kellam, S.G., see Ialongo, N. (79) 127
Khawaja, N.G. and Dyer, E.J.
Anxious Thoughts and Tendencies Scale: An investigation of factor structure and the psychometric properties on the basis of an Australian sample (79) 217
Kochman, F., see Millet, B. (79) 241
Koenig, A.L., see Ialongo, N. (79) 127
Kolodziej, M., see Weiss, R.D. (79) 279
Krebs, M.O., see Millet, B. (79) 241
Kusumakar, V., see Kutcher, S. (79) 177

Kutcher, S., Kusumakar, V., LeBlanc, J., Santor, D., Lagace, D. and Morehouse, R.
The characteristics of asymptomatic female adolescents at high risk for depression: the baseline assessment from a prospective 8-year study (79) 177

Lachausse, C., see Karege, F. (79) 187
Lagace, D., see Kutcher, S. (79) 177
Lalovic, A., Sequeira, A., DeGuzman, R., Chawky, N., Lesage, A., Seguin, M. and Turecki, G.
Investigation of completed suicide and genes involved in cholesterol metabolism (79) 25
Lam, D., Wright, K. and Smith, N.
Dysfunctional assumptions in bipolar disorder (79) 193
Lattanzi, L., see Benedetti, A. (79) 273
Laukkala, T., see Hämäläinen, J. (79) 105
LeBlanc, J., see Kutcher, S. (79) 177
Leiva, A., see Ezquiaga, E. (79) 63
Lerer, B., see Blairy, S. (79) 97
Lesage, A., see Lalovic, A. (79) 25
Levitan, R.D., see Gratzer, D. (79) 209
Light, K.C., see Straneva-Meuse, P.A. (79) 51
Lindeman, S., see Hämäläinen, J. (79) 105
Linotte, S., see Blairy, S. (79) 97
Loo, H., see Millet, B. (79) 241
Lunde, M., see Martiny, K. (79) 253

Macciardi, F., see Blairy, S. (79) 97
Maier, W., see Barkow, K. (79) 235
Malison, R.T., see Carpenter, L.L. (79) 285
Marchant, B.K., see Preston, G.A. (79) 297
Martiny, K., Simonsen, C., Lunde, M., Clemmensen, L. and Bech, P.
Decreasing TSH levels in patients with Seasonal Affective Disorder (SAD) responding to 1 week of bright light therapy (79) 253
Matthey, S., Kavanagh, D.J., Howie, P., Barnett, B. and Charles, M.
Prevention of postnatal distress or depression: an evaluation of an intervention at preparation for parenthood classes (79) 113
McCreary, B.K., see Ialongo, N. (79) 127
Mendlewicz, J., see Blairy, S. (79) 97
Milanova, V., see Blairy, S. (79) 97
Millet, B., Kochman, F., Gallarda, T., Krebs, M.O., Demonfaucon, F., Barrot, I., Bourdel, M.C., Olié, J.P., Loo, H. and Hantouche, E.G.
Phenomenological and comorbid features associated in obsessive–compulsive disorder: influence of age of onset (79) 241
Montejo, J., see Ezquiaga, E. (79) 63
Montes, J.M., Ferrando, L. and Saiz-Ruiz, J.
Remission in major depression with two antidepressant mechanisms: results from a naturalistic study (79) 229
Morehouse, R., see Kutcher, S. (79) 177
Mukherjee, S., see Sampson, E. (79) 223
Mullan, N., see Sampson, E. (79) 223
Müller-Oerlinghausen, B., Roggenbach, J. and Franke, L.
Serotonergic platelet markers of suicidal behavior—do they really exist? (79) 13

Müller-Oerlinghausen, B., see Baethge, C. (79) 43
Musetti, L., see Benedetti, A. (79) 273

Najavits, L.M., see Weiss, R.D. (79) 279
Nierenberg, A.A., see Perlis, R.H. (79) 291

O'Brien, J.T., see Thomas, A.J. (79) 81
Olié, J.P., see Millet, B. (79) 241
Otto, M.W., see Harlow, B.L. (79) 167

Papadimitriou, G.N., see Blairy, S. (79) 97
Papadimitriou, P., see Karege, F. (79) 187
Pearson, J.L., see Ialongo, N. (79) 127
Perlis, R.H., Smoller, J.W., Fava, M., Rosenbaum, J.F., Nierenberg, A.A. and Sachs, G.S.
The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder (79) 291
Pini, S., see Benedetti, A. (79) 273
Poduska, J., see Ialongo, N. (79) 127
Poikolainen, K., see Hämäläinen, J. (79) 105
Preston, G.A., Marchant, B.K., Reimherr, F.W., Strong, R.E. and Hedges, D.W.
Borderline personality disorder in patients with bipolar disorder and response to lamotrigine (79) 297
Price, L.H., see Carpenter, L.L. (79) 285
Price, J.S., Gardner Jr., R. and Erickson, M.
Can depression, anxiety and somatization be understood as appeasement displays? (79) 1

Rector, N.A., see Gratzer, D. (79) 209
Reimherr, F.W., see Preston, G.A. (79) 297
Roggenbach, J., see Müller-Oerlinghausen, B. (79) 13
Rosenbaum, J.F., see Perlis, R.H. (79) 291

Sachs, G.S., see Yildiz, A. (79) 247
Sachs, G.S., see Perlis, R.H. (79) 291
Saiz-Ruiz, J., see Montes, J.M. (79) 229
Sampson, E., Mukherjee, S., Ukoumunne, O.C., Mullan, N. and Bullock, T.
History of deliberate self-harm and its association with mood fluctuation (79) 223
Santor, D., see Kutcher, S. (79) 177
Schmidt, N.B., see Ialongo, N. (79) 127
Schwald, M., see Karege, F. (79) 187
Seguin, M., see Lalovic, A. (79) 25
Sequeira, A., see Lalovic, A. (79) 25
Serretti, A., see Blairy, S. (79) 97
Sheldon, T., see Gratzer, D. (79) 209
Simonsen, C., see Martiny, K. (79) 253
Smith, N., see Lam, D. (79) 193
Smolka, M.N., see Baethge, C. (79) 43
Smoller, J.W., see Perlis, R.H. (79) 291
Souery, D., see Blairy, S. (79) 97
Spiegelman, D., see Harlow, B.L. (79) 167
Stein, M.B. and Heimberg, R.G.
Well-being and life satisfaction in generalized anxiety disorder: comparison to major depressive disorder in a community sample (79) 161
Straneva-Meuse, P.A., Light, K.C., Allen, M.T., Golding, M. and Girdler, S.S.
Bupropion and paroxetine differentially influence cardiovascular and neuroendocrine responses to stress in depressed patients (79) 51
Strong, R.E., see Preston, G.A. (79) 297

Tavares, A., see Volpe, F.M. (79) 201
Tényi, T., Trixler, M., Csábi, G. and Jeges, S.
Minor physical anomalies in non-familial unipolar recurrent major depression (79) 259
Thomas, A.J., Kalaria, R.N. and O'Brien, J.T.
Depression and vascular disease: what is the relationship? (79) 81
Toneatto, T., see Gratzer, D. (79) 209
Trixler, M., see Tényi, T. (79) 259
Troisi, A. and D'Argenio, A.
The relationship between anger and depression in a clinical sample of young men: the role of insecure attachment (79) 269
Turecki, G., see Lalovic, A. (79) 25
Tyrka, A.R., see Carpenter, L.L. (79) 285

Ukoumunne, O.C., see Sampson, E. (79) 223

Van Dorsselaer, S., see Cuijpers, P. (79) 71
Volpe, F.M. and Tavares, A.
Manic patients receiving ECT in a Brazilian sample (79) 201

Webb, R., see Douglas, J. (79) 263
Weiss, R.D., Kolodziej, M., Griffin, M.L., Najavits, L.M., Jacobson, L.M. and Greenfield, S.F.
Substance use and perceived symptom improvement among patients with bipolar disorder and substance dependence (79) 279
Wilhelm, K., Boyce, P. and Brownhill, S.
The relationship between interpersonal sensitivity, anxiety disorders and major depression (79) 33
Wittchen, H.-U., see Barkow, K. (79) 235
Wright, K., see Lam, D. (79) 193

Yildiz, A. and Sachs, G.S.
Characteristics of rapid cycling bipolar-I patients in a bipolar speciality clinic (79) 247

ELSEVIER

Journal of Affective Disorders 79 (2004) 311 - 314

JOURNAL OF AFFECTIVE DISORDERS

www.elsevier.com/locate/jad

# Subject index

**Adolescent**; Depression; Female; Risk factors **79**, 177

**Affective disorder**; Depression; Evolution; Communication; Anxiety disorder; Somatoform disorder; Chronic fatigue syndrome; Appeasement; Submission **79**, 1

**African-Americans**; Major depression; Young adults **79**, 127

**Age of onset**; Obsessive–compulsive disorder; Early onset; Late onset; Depression; Tics **79**, 241

**Age of onset**; Rapid cycling; Gender **79**, 247

**Alcohol abuse**; Major depression; Anxiety disorders; Co-morbidity; Epidemiology; Community sample **79**, 209

**Anger**; Depression; Entrapment; Escape; Life events **79**, 149

**Anger**; Depression; Attachment **79**, 269

**Anger attacks**; Bipolar disorder; Depression; Phenomenology **79**, 291

**Antenatal classes**; Postnatal depression; Preparation; Fathers **79**, 113

**Antidepressant**; Depression; Remission; Serotonin; Noradrenaline **79**, 229

**Anxiety**; Major depression; Generalized anxiety disoder; Quality of life; Well-being; Health; **79**, 161

**Anxiety**; Cognition; Anxious thoughts; Anxious tendencies **79**, 217

**Anxiety disorder**; Depression; Evolution; Communication; Affective disorder; Somatoform disorder; Chronic fatigue syndrome; Appeasement; Submission **79**, 1

**Anxiety disorders**; Interpersonal sensitivity; Major depression **79**, 33

**Anxiety disorders**; Major depression; Alcohol abuse; Co-morbidity; Epidemiology; Community sample **79**, 209

**Anxious tendencies**; Anxiety; Cognition; Anxious thoughts **79**, 217

**Anxious thoughts**; Anxiety; Cognition; Anxious tendencies **79**, 217

**Appeasement**; Depression; Evolution; Communication; Affective disorder; Anxiety disorder; Somatoform disorder; Chronic fatigue syndrome; Submission **79**, 1

**Attachment**; Depression; Anger **79**, 269

**Atypical depression**; Seasonal Affective Disorder; Thyroid-stimulating hormone; TSH **79**, 253

**BDNF**; Bipolar disorder; cAMP-dependent PKA; Lymphoblast **79**, 187

**Behavioural activation system theory**; Dysfunctional attitudes; Bipolar disorder **79**, 193

**Biological markers**; Neurodevelopment; Minor physical anomalies; Unipolar recurrent major depression **79**, 259

**Bipolar**; Lamotrigine; Borderline personality disorder **79**, 297

**Bipolar depression**; Oxcarbazepine; Bipolar disorder; Mood-stabilizers; Mania; Carbamazepine **79**, 273

**Bipolar disorder**; Self-esteem; Social-adjustment **79**, 97

**Bipolar disorder**; cAMP-dependent PKA; BDNF; Lymphoblast **79**, 187

**Bipolar disorder**; Dysfunctional attitudes; Behavioural activation system theory **79**, 193

**Bipolar disorder**; Oxcarbazepine; Mood-stabilizers; Mania; Bipolar depression; Carbamazepine **79**, 273

**Bipolar disorder**; Substance abuse; Self-medication; Substance dependence; Dual diagnosis **79**, 279

**Bipolar disorder**; Depression; Anger attacks; Phenomenology **79**, 291

**Borderline personality disorder**; Lamotrigine; Bipolar **79**, 297

**Bupropion**; Paroxetine; Depression; Heart rate variability; Stress **79**, 51

**cAMP-dependent PKA**; Bipolar disorder; BDNF; Lymphoblast **79**, 187

**Carbamazepine**; Oxcarbazepine; Bipolar disorder; Mood-stabilizers; Mania; Bipolar depression **79**, 273

**Cerebrospinal fluid**; Interleukin-6; Cytokines; Depression; Psychoneuroimmunology; Mood disorder **79**, 285

**Cholesterol**; Completed suicide; Suicidal behavior; Genetic variation **79**, 25

doi:10.1016/S0165-0327(04)00067-9

**Chronic fatigue syndrome**; Depression; Evolution; Communication; Affective disorder; Anxiety disorder; Somatoform disorder; Appeasement; Submission **79**, 1

**Cognition**; Anxiety; Anxious thoughts; Anxious tendencies **79**, 217

**Communication**; Depression; Evolution; Affective disorder; Anxiety disorder; Somatoform disorder; Chronic fatigue syndrome; Appeasement; Submission **79**, 1

**Community sample**; Major depression; Anxiety disorders; Alcohol abuse; Co-morbidity; Epidemiology **79**, 209

**Co-morbidity**; Major depression; Anxiety disorders; Alcohol abuse; Epidemiology; Community sample **79**, 209

**Completed suicide**; Suicidal behavior; Genetic variation; Cholesterol **79**, 25

**Cytokines**; Cerebrospinal fluid; Interleukin-6; Depression; Psychoneuroimmunology; Mood disorder **79**, 285

**Deliberate self-harm**; Suicidality; Depression **79**, 223

**Deliberate self-harm**; Serious suicide attempt; Depression; Suicide risk; Suicide prevention **79**, 263

**Depression**; Evolution; Communication; Affective disorder; Anxiety disorder; Somatoform disorder; Chronic fatigue syndrome; Appeasement; Submission **79**, 1

**Depression**; Bupropion; Paroxetine; Heart rate variability; Stress **79**, 51

**Depression**; Vascular disease; Epidemiology; Neuroimaging; Neuropathology **79**, 81

**Depression**; Effectiveness; Meta-analysis; Outcome; Pindolol; SSRI **79**, 137

**Depression**; Entrapment; Escape; Anger; Life events **79**, 149

**Depression**; Female; Adolescent; Risk factors **79**, 177

**Depression**; Remission; Antidepressant; Serotonin; Noradrenaline **79**, 229

**Depression**; Obsessive–compulsive disorder; Age of onset; Early onset; Late onset; Tics **79**, 241

**Depression**; Deliberate self-harm; Suicidality **79**, 223

**Depression**; Deliberate self-harm; Serious suicide attempt; Suicide risk; Suicide prevention **79**, 263

**Depression**; Anger; Attachment **79**, 269

**Depression**; Cerebrospinal fluid; Interleukin-6; Cytokines; Psychoneuroimmunology; Mood disorder **79**, 285

**Depression**; Bipolar disorder; Anger attacks; Phenomenology **79**, 291

**Dual diagnosis**; Bipolar disorder; Substance abuse; Self-medication; Substance dependence **79**, 279

**Dysfunctional attitudes**; Bipolar disorder; Behavioural activation system theory **79**, 193

**Early onset**; Obsessive–compulsive disorder; Age of onset; Late onset; Depression; Tics **79**, 241

**Effectiveness**; Depression; Meta-analysis; Outcome; Pindolol; SSRI **79**, 137

**Electroconvulsive therapy (ECT)**; Mania; Inpatients; Treatment decision **79**, 201

**Entrapment**; Depression; Escape; Anger; Life events **79**, 149

**Epidemiology**; Depression; Vascular disease; Neuroimaging; Neuropathology **79**, 81

**Epidemiology**; Major depression; Anxiety disorders; Alcohol abuse; Co-morbidity; Community sample **79**, 209

**Epidemiology**; Mixed anxiety–depression; Stability; Validity **79**, 235

**Escape**; Depression; Entrapment; Anger; Life events **79**, 149

**Evolution**; Depression; Communication; Affective disorder; Anxiety disorder; Somatoform disorder; Chronic fatigue syndrome; Appeasement; Submission **79**, 1

**Fathers**; Postnatal depression; Antenatal classes; Preparation **79**, 113

**Female**; Depression; Adolescent; Risk factors **79**, 177

**Functional disability**; Minor depression; Major depression; Heath care use; Prospective study **79**, 71

**Gender**; Rapid cycling; Age of onset **79**, 247

**Generalized anxiety disoder**; Major depression; Anxiety; Quality of life; Well-being; Health; **79**, 161

**Genetic variation**; Completed suicide; Suicidal behavior; Cholesterol **79**, 25

**Health**; Major depression; Generalized anxiety disoder; Anxiety; Quality of life; Well-being; **79**, 161

**Health services**; Major depression; Use **79**, 105

**Heath care use**; Minor depression; Major depression; Functional disability; Prospective study **79**, 71

**Heart rate variability**; Bupropion; Paroxetine; Depression; Stress **79**, 51

**Inpatients**; Mania; Electroconvulsive therapy (ECT); Treatment decision **79**, 201

**Interleukin-6**; Cerebrospinal fluid; Cytokines; Depression; Psychoneuroimmunology; Mood disorder **79**, 285

**Interpersonal sensitivity**; Anxiety disorders; Major depression **79**, 33

**Lamotrigine**; Bipolar; Borderline personality disorder **79**, 297

**Late onset**; Obsessive–compulsive disorder; Age of onset; Early onset; Depression; Tics **79**, 241

**Latency**; Schizoaffective disorder; Prophylaxis; Predictors; Lithium **79**, 43

**Life events**; Depression; Entrapment; Escape; Anger **79**, 149

**Lithium**; Schizoaffective disorder; Prophylaxis; Predictors; Latency **79**, 43

**Lymphoblast**; Bipolar disorder; cAMP-dependent PKA; BDNF **79**, 187

**Major depression**; Interpersonal sensitivity; Anxiety disorders **79**, 33

**Major depression**; Personality; Psychosocial variables; Outcome **79**, 63

**Major depression**; Minor depression; Functional disability; Heath care use; Prospective study **79**, 71

**Major depression**; Health services; Use **79**, 105

**Major depression**; African-Americans; Young adults **79**, 127

**Major depression**; Generalized anxiety disoder; Anxiety; Quality of life; Well-being; Health; **79**, 161

**Major depression**; Menstruation; Pregnancy; Risk factors **79**, 167

**Major depression**; Anxiety disorders; Alcohol abuse; Co-morbidity; Epidemiology; Community sample **79**, 209

**Mania**; Inpatients; Electroconvulsive therapy (ECT); Treatment decision **79**, 201

**Mania**; Oxcarbazepine; Bipolar disorder; Mood-stabilizers; Bipolar depression; Carbamazepine **79**, 273

**Menstruation**; Major depression; Pregnancy; Risk factors **79**, 167

**Meta-analysis**; Depression; Effectiveness; Outcome; Pindolol; SSRI **79**, 137

**Minor depression**; Major depression; Functional disability; Heath care use; Prospective study **79**, 71

**Minor physical anomalies**; Neurodevelopment; Unipolar recurrent major depression; Biological markers **79**, 259

**Mixed anxiety–depression**; Stability; Validity; Epidemiology **79**, 235

**Mood disorder**; Cerebrospinal fluid; Interleukin-6; Cytokines; Depression; Psychoneuroimmunology **79**, 285

**Mood-stabilizers**; Oxcarbazepine; Bipolar disorder; Mania; Bipolar depression; Carbamazepine **79**, 273

**Neurodevelopment**; Minor physical anomalies; Unipolar recurrent major depression; Biological markers **79**, 259

**Neuroimaging**; Depression; Vascular disease; Epidemiology; Neuropathology **79**, 81

**Neuropathology**; Depression; Vascular disease; Epidemiology; Neuroimaging **79**, 81

**Noradrenaline**; Depression; Remission; Antidepressant; Serotonin **79**, 229

**Obsessive–compulsive disorder**; Age of onset; Early onset; Late onset; Depression; Tics **79**, 241

**Outcome**; Major depression; Personality; Psychosocial variables **79**, 63

**Outcome**; Depression; Effectiveness; Meta-analysis; Pindolol; SSRI **79**, 137

**Oxcarbazepine**; Bipolar disorder; Mood-stabilizers; Mania; Bipolar depression; Carbamazepine **79**, 273

**Paroxetine**; Bupropion; Depression; Heart rate variability; Stress **79**, 51

**Personality**; Major depression; Psychosocial variables; Outcome **79**, 63

**Phenomenology**; Bipolar disorder; Depression; Anger attacks **79**, 291

**Pindolol**; Depression; Effectiveness; Meta-analysis; Outcome; SSRI **79**, 137

**Postnatal depression**; Antenatal classes; Preparation; Fathers **79**, 113

**Predictors**; Schizoaffective disorder; Prophylaxis; Latency; Lithium **79**, 43

**Pregnancy**; Major depression; Menstruation; Risk factors **79**, 167

**Preparation**; Postnatal depression; Antenatal classes; Fathers **79**, 113

**Prophylaxis**; Schizoaffective disorder; Predictors; Latency; Lithium **79**, 43

**Prospective study**; Minor depression; Major depression; Functional disability; Heath care use **79**, 71

**Psychoneuroimmunology**; Cerebrospinal fluid; Interleukin-6; Cytokines; Depression; Mood disorder **79**, 285

**Psychosocial variables**; Major depression; Personality; Outcome **79**, 63

**Quality of life**; Major depression; Generalized anxiety disoder; Anxiety; Well-being; Health; **79**, 161

**Rapid cycling**; Age of onset; Gender **79**, 247

**Remission**; Depression; Antidepressant; Serotonin; Noradrenaline **79**, 229

**Risk factors**; Major depression; Menstruation; Pregnancy **79**, 167

**Risk factors**; Depression; Female; Adolescent **79**, 177

**Schizoaffective disorder**; Prophylaxis; Predictors; Latency; Lithium **79**, 43

**Seasonal Affective Disorder**; Thyroid-stimulating hormone; TSH; Atypical depression **79**, 253

**Self-esteem**; Bipolar disorder; Social-adjustment **79**, 97

**Self-medication**; Bipolar disorder; Substance abuse; Substance dependence; Dual diagnosis **79**, 279

**Serious suicide attempt**; Deliberate self-harm; Depression; Suicide risk; Suicide prevention **79**, 263

**Serotonin**; Depression; Remission; Antidepressant; Noradrenaline **79**, 229

**Social-adjustment**; Bipolar disorder; Self-esteem **79**, 97

**Somatoform disorder**; Depression; Evolution; Communication; Affective disorder; Anxiety disorder; Chronic fatigue syndrome; Appeasement; Submission **79**, 1

**SSRI**; Depression; Effectiveness; Meta-analysis; Outcome; Pindolol **79**, 137

**Stability**; Mixed anxiety–depression; Validity; Epidemiology **79**, 235

**Stress**; Bupropion; Paroxetine; Depression; Heart rate variability **79**, 51

**Submission**; Depression; Evolution; Communication; Affective disorder; Anxiety disorder; Somatoform disorder; Chronic fatigue syndrome; Appeasement **79**, 1

**Substance abuse**; Bipolar disorder; Self-medication; Substance dependence; Dual diagnosis **79**, 279

**Substance dependence**; Bipolar disorder; Substance abuse; Self-medication; Dual diagnosis **79**, 279

**Suicidal behavior**; Completed suicide; Genetic variation; Cholesterol **79**, 25

**Suicidality**; Deliberate self-harm; Depression **79**, 223

**Suicide prevention**; Deliberate self-harm; Serious suicide attempt; Depression; Suicide risk **79**, 263

**Suicide risk**; Deliberate self-harm; Serious suicide attempt; Depression; Suicide prevention **79**, 263

**Thyroid-stimulating hormone**; Seasonal Affective Disorder; TSH; Atypical depression **79**, 253

**Tics**; Obsessive–compulsive disorder; Age of onset; Early onset; Late onset; Depression **79**, 241

**Treatment decision**; Mania; Inpatients; Electroconvulsive therapy (ECT) **79**, 201

**TSH**; Seasonal Affective Disorder; Thyroid-stimulating hormone; Atypical depression **79**, 253

**Unipolar recurrent major depression**; Neurodevelopment; Minor physical anomalies; Biological markers **79**, 259

**Use**; Major depression; Health services **79**, 105

**Validity**; Mixed anxiety–depression; Stability; Epidemiology **79**, 235

**Vascular disease**; Depression; Epidemiology; Neuroimaging; Neuropathology **79**, 81

**Well-being**; Major depression; Generalized anxiety disoder; Anxiety; Quality of life; Health; **79**, 161

**Young adults**; Major depression; African-Americans **79**, 127